Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07755072

The Effect of Ligament of Marshall Excision During Minimally Invasive Cardiac Surgery-Coronary Artery Bypass Grafting (MICS-CABG) on the Prevention of Postoperative New-Onset Atrial Fibrillation: A Multicenter, Prospective, Randomized, Triple-Blinded Study

After heart bypass surgery, many patients develop a heart rhythm problem called postoperative atrial fibrillation, or POAF for short. This issue happens to 20%-40% of all bypass patients. Even with smaller, less invasive surgical cuts or robot-assisted heart bypass operations, between 4.8% and 18.4% of people still get POAF.

When POAF occurs, patients usually stay in the hospital longer and face higher medical bills. It also raises chances of serious complications like stroke, heart failure and heart attacks, and lowers long-term survival rates. Stopping POAF early is therefore key to helping patients recover better after surgery.

POAF comes from two main causes: personal health risks and stress from the surgery itself. Older age, high blood pressure, heart failure, lung disease, diabetes and overweight all make people more likely to develop irregular heart rhythms after an operation. Surgical trauma also plays a big role: cutting the breastbone, fluid building up around the heart, inflammation from heart-lung machines, pulling or stitching heart tissue, and unbalanced nerve signals during recovery can all spark POAF. Earlier studies have shown simple surgical adjustments can lower POAF risk safely, giving us a good basis to improve current surgery methods.

The Ligament of Marshall is a fibrous bundle-like structure left over from heart development before birth. Its special tissue structure makes it easy to trigger chaotic heart beats. It holds muscle tissue that creates looping abnormal electrical signals, plus nerve clusters that overactivate the body's stress response after surgery - this is a major cause of POAF. Doctors who fix irregular heart rhythms with catheter burns already target this ligament to stop repeat atrial fibrillation. Major heart surgery for long-term irregular heartbeats also routinely cuts this ligament without adding extra surgical risks.

Our study will collect real clinical data to deepen the understanding of POAF and partial denervation therapy. Cutting the Ligament of Marshall during minimally invasive cardiac surgery-coronary artery bypass grafting (MICS-CABG) is an easy, low-risk step with no extra risk of collateral injury. We hope this method can lower the chance of irregular heartbeats after surgery, reduce the need for rhythm-control drugs and their side effects, and help patients maintain stable heart function and better daily life right after surgery.

For MICS-CABG, doctors do not need extra complicated steps to see and cut the Ligament of Marshall. We only make a small cut between the ribs on the left chest. After pericardial incision and suspension, this fibrous bundle-like structure is clearly visible and simple to operate on. Compared with traditional open-heart surgery that splits the whole breastbone, this small-cut approach avoids rough handling of the left heart and lessens overall surgical stress on patients.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China

Location contact

Yunpeng Ling

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18-80 years;
  • Coronary artery lesions meeting the indications for surgical revascularization, with planned MICS-CABG;
  • Signed an informed consent form agreeing to participate in the study;

Exclusion criteria

  • Patients with preoperative hemodynamic instability requiring emergency surgery;
  • History of paroxysmal or persistent atrial fibrillation prior to surgery;
  • Echocardiographic left atrial anteroposterior diameter (APD) ≥ 60 mm;
  • Patients with ejection fraction (EF) < 40%, left ventricular diastolic dimension (LVDD) > 60 mm, left ventricular aneurysm, or severe arrhythmia who are at high risk of intraoperative hemodynamic instability;
  • Patients with concomitant mitral stenosis or regurgitation of moderate severity or greater;
  • Patients undergoing concurrent valve surgery or other intracardiac corrective procedures;
  • Patients with a history of renal insufficiency;
  • Patients receiving intra-aortic balloon pump (IABP) or extracorporeal membrane oxygenation (ECMO) circulatory support preoperatively;
  • Patients taking antiarrhythmic drugs other than beta-blockers prior to surgery, such as propafenone or amiodarone;
  • History of cardiac or thoracic surgery;
  • Poor pulmonary function, with a preoperative arterial blood gas analysis oxygen partial pressure (PaO₂) < 60 mmHg at rest without oxygen supplementation;
  • Patients with a preoperative pacemaker implant;

Treatment and study plan

MICS-CABG combined with excision of the Ligament of Marshall

Procedure

This intervention refers to excision of the Ligament of Marshall performed during MICS-CABG. Patients in this group will undergo routine MICS-CABG plus this extra surgical excision.

Primary outcomes

  1. Primary Endpoints

    Time frame: During the postoperative hospital stay

    Each episode of POAF lasting ≥30 seconds during the postoperative hospital stay.

Secondary outcomes

  1. Secondary Endpoints

    Time frame: Postoperative month 1

    Burden of POAF; need for Class I and III antiarrhythmic drugs (Vaughan Williams classification) and electrical cardioversion; postoperative length of hospital stay; postoperative duration of mechanical ventilation; reoperation due to bleeding; Incidence of non-atrial fibrillation arrhythmias at 1 month postoperatively (wristband + central adjudication)

Study contacts

Contact information is provided by the study sponsor or research team.

Jian Song

CONTACT

[email protected]

Yunpeng Ling

CONTACT

[email protected]

+8615611963466

Sponsors and collaborators

Lead sponsor

Peking University Third Hospital

Other

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Aug 10, 2026
Registry last updated
Aug 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.